

DATE: December 23, 1996 SHEET 1 of 1

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

5778.US.01

SERIAL NO.

08/687,774

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))



D.W. Norbeck, et al

FILING DATE

June 26, 1996

GROUP

1814

FFB

11.1997
1612

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES	NO
CA	✓	9 6 0 4 9 1 3	22 Feb 1996	PCT			X	
CA	—	9 5 3 3 4 6 4	14 Dec 1995	PCT			X	
CA	✓	9 5 1 1 9 9 2	4 May 1995	PCT			X	
CA		0 6 9 1 3 4 5	10.01. 96	EPO			X	

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CA	✓	S. Vella, RATIONALE AND EXPERIENCE WITH REVERSE TRANSCRIPTASE INHIBITORS AND PROTEASE INHIBITORS, Journ Of Acquired Immune Def. Syndrome & Humane Retro. 10(Suppl. 1) S58-S61 1995
CA	✗	J. Craig, et al., Int. Conf. AIDS 9(1993) PO-A25-0602 RO 31-8959, AN INHIBITOR OF HIV PROTEINASE, ACTS BENEFICIALLY WITH OTHER ANTIVIRAL AGENTS IN 2- AND 3-WAY COMBINATIONS IN VITRO
	✓	J. Partaledis, et al. Journal of Virology Sept 1995 p. 5228-5235, IN VITRO SELECTION AND CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) ISOLATES WITH REDUCED SENSITIVITY TO HYDROXYETHYLAMINO SULFONAMIDE INHIBITORS OF HIV-1 ASPARTYL PROTEASE
CA		D. Kempf, et al., 3RD CONF RETRO AND OPPORTUN INFECT (US) Jan 28-Feb 1, 1996 p. 79.
CA	✗	J. James, AIDS TREATMENT NEWS, no. 231 Sept 29, 1995

EXAMINER

AISLACK

DATE CONSIDERED

4-14-97

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)